Daniel Nevo
@DanielNevo
Followers
390
Following
3K
Media
74
Statuses
716
Associate Prof. @TelAvivUni Stat & OR Department. (Bio)statistics, causal inference, etc.
Joined April 2015
New version of our paper!.
Hey ๐ #econtwitter new version of the RD-DID paper - Some of whats new:.- Iden. and est. of composition effects.- Different SE under cross section / panel w. constant or time-varying running variables.- A package (my first!). Cheers!.
0
0
4
RT @UriObolski: Our new paper, led by Yaki Saciuk, is out in @NatureComms!. We leverage allergy to penicillin as aโฆ.
0
3
0
RT @AmitMoscovich: ืืขืจื ืืืืืจ ืืื ืืืงืืืจื ื ืืงืืืฆื ืฉืื ืืืื ืืืจืกืืืช ืช"ื (ืืืืืืืืื ืืง ืืืื) ืฉืืืื ืืฉืืืข ืฉืขืืจ ืืช ืืฉืชื ืขื ืืจ ืืคืืืืข ืืจืฆืื ื ืืืคื.โฆ.
0
82
0
Check out our new working paper on correcting invalid regression discontinuity designs. Led by talented Econ PhD student Dor Leventer (@DorLev3) ! . ๐
arxiv.org
Regression Discontinuity (RD) designs rely on the continuity of potential outcome means at the cutoff, but this assumption often fails when other treatments or policies are implemented at this...
๐ข@DanielNevo and I have a new WP out๐ข. In the paper, we present a general framework for identification in RD designs when continuity is violated using multiple time period data, which we term RD-DID. A thread 1/n.#EconTwitter #Econometrics.
0
1
13
RT @TAD_Tau: Congratulations to TAD members: Prof. Yoav Benjamini, Prof. Daniel Yekutieli, and Prof. Ruth Heller for winning the prestigiouโฆ.
0
2
0
RT @DanieliOren: Falsification tests are often too harsh and people can find problems even when their IV is exogenous. Come hear more inโฆ.
0
7
0
RT @cepr_org: New CEPR Discussion Paper - DP19127.Negative Control Falsification Tests for Instrumental Variable Designs.@DanieliOren, @Danโฆ.
0
4
0
RT @SVansteelandt: I have several exciting openings for PhD students and postdocs in the context of my advanced ERC grant #ERCAdG on Assumpโฆ.
0
24
0
RT @yuvalbenj: #ืืืืืืืืืืจ ืืืงืจ ืืื, ืืืื ืื ืก ืืืืืื ืืืฉืจืืื ืืกืืืืกืืืงื ืืกืคืจืื ืืืืืืืช. ืืชืืืืื ืขื ืืืฉื ื ืชืื ืื ืืืืจืื - ืคืจืืค' ืงืจืื ื ืืื ืืกืคโฆ.
0
1
0
#CausalTwitter, check out our new paper๐!. We provide theoretical justification for and tons of practical guidance on using negative controls for falsification tests for IV exogeneity. I had the privilege of presenting this paper at the last @TheEuroCIM.
WP๐จ with @danzeltzer @DanielNevo @B_WNSN & Walk. If you used an IV, you likely ran a falsification or placebo test for exogeneity. We show these tests can be *too harsh*. They can flag issues even if the IV is exogenous.#EconTwitter #CausalInference.๐งต>>
0
5
16
RT @DanieliOren: WP๐จ with @danzeltzer @DanielNevo @B_WNSN & Walk. If you used an IV, you likely ran a falsification or placebo test for exโฆ.
0
25
0
RT @danzeltzer: ๐๏ธFri 10am at SOLE: @DanieliOren presents our work on falsification tests for IV designs!
0
2
0
ื ืืฉืชื: "SUTVA assumption".
ืืืงืื ืืจืืืฉ ืื ืฉืืืืืืืจ ืืื ืืกืืื ืืืื ืืงืืง ืืืคืขืื ืืืช ืืฉืืื ืืคืื-.ืืขืืืืช ืฉื ืื ืฉืื ืืืื ืช ืืงืื ืกืคื ืฉื ืจืืฉืืช ืชืืืืช. ืื ื ืืชืืื-.ืืืจื ืืืคืฉืื ืฉื ืืชืืืืช ืืืืืื: "ืกื"ื ืืืืืืช".
1
0
6
RT @StatStaci5: Submissions are open for Invited Session and Workshop proposals for the International Conference on Health Policy Statisticโฆ.
0
7
0
Me: ChatGPT, can you have a look at slide number five in my slides and let me know if there are any typos or grammar issues? . ChatGPT:
0
0
4
For more details, check out our paper, correspondence and R code:.๐ ๐ฅ๏ธ ๐๏ธ#VaccineEfficacy #EpiTwitter #CausalInference.
thelancet.com
In their Article, Mary-Claire R Walsh and colleagues1 present results from a phase 2 clinical trial of the TV005 tetravalent dengue vaccine. This trial provides important evidence for the safety and...
0
0
1
In a recent phase 2 Dengue vaccine trial, side effects varied between vaccine and placebo arms. We call for phase 3 trials to measure participantsโ beliefs about receiving the active vaccine or placebo. See our Correspondence in @TheLancetInfDis .
thelancet.com
In their Article, Mary-Claire R Walsh and colleagues1 present results from a phase 2 clinical trial of the TV005 tetravalent dengue vaccine. This trial provides important evidence for the safety and...
1
0
1
These issues are exacerbated under broken blinding. Especially when side effects differ between treatment and placebo, trial participants might have knowledge about their status. We study and illustrate this issue using data from an influenza vaccine trial.
1
0
1
โ ๏ธTechnical details 2:.How can we learn what would happen when vaccine status is known, based on data from a blinded trial?.We consider a belief variable, capturing what participants think they received โ vaccine or placebo. We show how measuring belief can help provide an answer.
1
0
0